The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

RESULTS: Efficacy was evaluated over 713 patients. Averaged over 12 weeks, higher proportions of patients on prucalopride 2 mg (19.5%; p<0.01), 4 mg (23.6%; p<0.001) had three or more SCBM/week ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S.

ANI Pharmaceuticals, Inc. (ANIP) announced Thursday the launch of Prucalopride Tablets, which is the generic version of the reference ...

ANI Pharmaceuticals introduces US FDA approved prucalopride tablets: Princeton, New Jersey Friday, January 3, 2025, 14:00 Hrs [IST] ANI Pharmaceuticals, Inc., a diversified biopha ...

ANI Pharmaceuticals, Inc. announced the launch of its Prucalopride Tablets, a generic version of the drug Motegrity®, following final FDA approval of their Abbreviated New Drug Application.

ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, the company has launched Prucalopride Tablets. ANI’s Prucalopride ...

ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, the company has ...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration ...

ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the first generic for ...